Keywords: AGEs; DPP-4; Proximal tubular cells; Inflammation; Diabetic nephropathy;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: DKD; diabetic kidney disease; RAAS; renin-angiotensin-aldosterone system; ESRD; end-stage renal disease; T1DM; type I diabetes mellitus; T2DM; type II diabetes mellitus; CVD; cardiovascular disease; GFR; glomerular filtration rate; AER; albumin excretion
Keywords: Cardiovascular diesease; Dipeptidyl peptidase 4 inhibitor; Atherosclerosis; Heart failure; Myocardial infarction; AMI; acute myocardial infarction; BNP; Brain natriuretic peptide; CD26; cluster of differentiation 26; CHD; coronary heart disease; CKD; chro
Keywords: Vildagliptin; Drug-induced liver injury; Hypersensitivity; Covalent binding; Nucleophilic trapping agents; ALG; alogliptin; ANG; anagliptin; CRP; C-reactive protein; CYP; cytochrome P450; DILI; drug-induced liver injury; DLST; drug-induced lymphocyte stim
Keywords: Functional foods; Bioactive peptides; Whey proteins; Downstream process; Industrial scale-up; Peptide enrichment techniques; FOSHU; Foods for Specified Health Uses; PDCAAS; protein digestibility corrected amino acid score; BCAAs; branched-chain amino acid
Keywords: ADA; American Diabetes Association; BMI; body mass index; CGM; continuous glucose monitoring; DPP-4; dipeptidyl peptidase 4; GLP-1; glucagon-like peptide 1; mTORC1/2; mammalian target of rapamycin complex 1/2; OGTT; oral glucose tolerance test; PTDM; post
Keywords: AGEs; Advanced glycation end products; ADMA; Asymmetric dimethylarginine; cAMP; Cyclic adenosine monophosphate; DPP-4; Dipeptidyl peptidase 4; GLP-1; Glucagon-like peptide 1; GLP-1R; Glucagon-like peptide 1 receptor; HMGB-1; High mobility group box 1 prot
Keywords: Arthralgia; Dipeptidyl peptidase-4 inhibitors; Meta-analysis; Systematic review; DPP-4; Dipeptidyl peptidase-4; FDA; Food and Drug Administration; GIP; Glucose-dependent insulinotropic peptide; GLP-1; Glucagon-like peptide-1; IDF; International Diabetes F
Keywords: GQD; Gegen Qinlian decoction; T2DM; type 2 diabetes; RCTs; randomized clinical trials; AMPK; AMP-activated protein kinase; DPP-4; dipeptidyl peptidase-4; TCM; traditional Chinese medicines; OR; odds ratio; CI; confidence intervals; FPG; fasting plasma glu
Keywords: cardiac fibrosis; Cardiac hypertrophy; Collagen; DPP-4; Heart failure;
Keywords: Biologics; asthma; urticaria; nasal polyps; mAbs; cytokines; IgE; CAPS; Cryopyrin-associated periodic syndrome; DPP-4; Dipeptidyl peptidase 4; FDA; US Food and Drug Administration; Feno; Fraction of exhaled nitric oxide; IVIG; Intravenous immunoglobulin;
Keywords: Type 1 diabetes; DPP-4; GLP-1; Incretin;
Keywords: Diabetes mellitus; Glucagon-like peptide-1 agonists; Microvascular events; Macrovascular events; Retinopathy; Nephropathy; Cardiovascular events; GLP-1; Glucagon-like peptide-1; DM; Type 2 diabetes mellitus; CV; Cardiovascular; MI; Myocardial Infarction;
Keywords: Enteroendocrine Cells; Obesity; Gastrointestinal Peptides; Apo A-IV; apolipoprotein A-IV; BA; bile acids; CB1R; cannabinoid receptor 1 receptor CB1R; CCK; cholecystokinin; CCK-1R; CCK-1 receptor; CNS; central nervous system; DAG; des-acyl ghrelin; DIO; di
Keywords: Genistein; Morris water maze; Nitric oxide; IL-1β; TNF-α; AChE; acetylcholinesterase; ANCOVA; analysis of co-variance; ChE; cholinesterase; DACD; diabetes associated cognitive decline; DMSO; dimethyl sulfoxide; DNA; deoxyribonucleic acid; DPP-4; dipepti
Keywords: Macrophage; Adipose; Inflammation; Obesity; Fibrosis; Insulin; AMPK; AMP-activated protein kinase; ATM; adipose tissue macrophages; CRP; C-reactive protein; DIO; diet-induced obesity; DPP-4; dipeptidyl peptidase-4; FFA; free fatty acids; GLP-1; glucagon-l
Keywords: AP; action potential; CaMKII; Ca2+/calmodulin-dependent protein kinase II; CaT; Ca2+ transient; dF/dtmax; rate of contraction force rise; dF/dtmin; rate of contraction force fall; dP/dtmax; LV pressure rise; dP/dtmin; LV pressure fall; DPP-4; dipeptidyl p
Keywords: AKI; acute kidney injury; CKD; chronic kidney disease; DPP-4; dipeptidyl peptidase-4; ICD-9-CM; International Classification of Disease, Ninth Revision, Clinical Modification; NHIRD; National Health Insurance Research Database; OR; odds ratios; T2DM; type
Keywords: DPP-4; Type 1 diabetes; Complications; Liver function;
Keywords: BMI; Body mass index; DPP-4; Dipeptidyl peptidase IV; FDA; Food and Drug Administration; GLP-1; Glucagon-like peptide 1; Hb; Hemoglobin; INGAP; Islet cell neogenesis-associated protein; RYGB; Roux-en-Y gastric bypass; T2D; Type 2 diabetes;
Keywords: cardiovascular outcomes; dipeptidyl peptidase-4; glucagon-like peptide-1 receptor agonist; BP; blood pressure; CI; confidence interval; CKD; chronic kidney disease; CV; cardiovascular; DPP-4; dipeptidyl-aminopeptidase-4; DPP-4i; dipeptidyl peptidaseâ
Keywords: CRP; C-reactive protein; HDL; high density lipoprotein; LDL; low density lipoprotein; PPARγ; peroxisome proliferator activated receptor-γ; DPP-4; dipeptidyl peptidase-4; GLP-1; glucagon like peptide-1; TRIB3; tribbles homolog 3; ATF-4; activating transc
Keywords: CME; Clathrin-mediated endocytosis; COX; Cyclooxygenase; CPP; Cell-penetrating peptides; CSK; CSKSSDYQC peptide; CvME; Lipid raft/caveolae-mediated endocytosis; Cys; Cysteine; DMEC; Dimethylethyl chitosan; DEMC; Diethylmethyl chitosan; DPP-4; Dipeptidil p
Keywords: DPP-4; GLP-1; Treatment; Vomiting; CI; confidence interval; DCCT; Diabetes Control and Complications Trial; DPP; dipeptidylpeptidase; EDIC; Epidemiology of Diabetes Intensive Complications; GE; gastric emptying; GI; gastrointestinal; GIP; glucose-dependen
Keywords: GLUT; Glucose transporter; T1DM; Type-1 diabetes mellitus; T2DM; Type-2 diabetes mellitus; PKB/Akt; protein kinase B; GSK-3; glycogen synthase kinase-3; PGC-1α; peroxisome proliferator-activated receptor gamma coactivator-1α; FOXO; forkhead box O; VLDL;
Keywords: Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Thiazolinediones; Pioglitazone; Dipeptidyl peptidase 4 (DPP-4) inhibitors; Glucagon-like peptide-1 receptor agonists (GLP-1RA); BCAAs; branched-chain amino acids; ARB; angioten
Keywords: DPP-4; dipeptidyl peptidase 4; GLP-1; glucagon-like peptide-1; NC; bombesin/neuromedin C; GLP-1; Lymph; DPP-4; Portal vein; Lamina propria; Neuromedin C;
Keywords: Glycated albumin; Glycosylated hemoglobin; Glucose lowering medication; Taiwan; Reference range; Atherosclerosis; Prevention; ALT; Alanine aminotransferase; XGI; Alpha-Glucosidase Inhibitor; BG; Biguanides; CRE; Creatinine; DM; Diabetes Mellitus; DPP-4; D
Keywords: Crossover studies; Nitrites; Nitrates; Blood glucose; Hyperglycemia; Blood glucose; Insulin; ANOVA; analysis of variance; BMI; body mass index; DPP-4; dipeptidyl peptidase 4; HbA1c; glycated hemoglobin; HOMA-IR; homeostatic model of insulin resistance; iA
Keywords: GV; glycaemic variability; HbA1c; glycosylated hemoglobin; T2DM; type 2 diabetes mellitus; FBG; fasting blood glucose; SMBG; self-monitoring of blood glucose; IDF; International Diabetes Federation; SDBG; standard deviation of blood glucose; LAGE; largest
Keywords: GLP-1; glucagon-like peptide 1; 25OHD; 25-hydroxyvitamin D; RDA; recommended daily allowance; IGF-1; insulin-like growth factor 1; HDL; high density lipoprotein; HOMA-IR; homeostatic model assessment of insulin resistance; HbA1c; glycated hemoglobin; HFD;
Keywords: GIP; glucose-dependent insulinotropic polypeptide; GLP-1; glucagon-like peptide-1; DPP-4; dipeptidyl peptidase-4; BMI; body mass index; CNS; central nervous system; EMA; European Medicines Agency; FDA; US Food and Drug Administration; (Pro3)GIP; proline-3
Keywords: DPP-4; SGLT-2; GLP-1 Agonists; cardiovascular; type 2 diabetes;
Keywords: Chalcone; Diabetes; DPP-4; α-Glucosidase; PPAR-γ; PTP1B
Keywords: Análogos del GLP-1; Célula beta; Diabetes mellitus tipo 2; DPP-4; GIP; GLP-1; Glucagón; Insulina; Obesidad; Vaciamiento gástrico; Beta cell; DPP-4; Gastric emptying; GIP; GLP-1; GLP-1 analogs; Glucagon; Insulin; Obesity; Type 2 diabetes mellitus;
Keywords: DPP-4; dipeptidyl peptidase-4; GLP-1; glucagon-like peptide-1; SD; Sprague-Dawley; NF-κB; nuclear factor-κB; GIP; gastric inhibitory polypeptide; ICAM-1; intercellular adhesion molecule-1; PAM; periodic acid-methenamine silver; cAMP; cyclic AMP; CRP;
Keywords: Glycated hemoglobin (HbA1c); Body weight; Postprandial plasma glucose (PPG); AE; adverse event; BMI; body mass index; DPP-4; dipeptidyl peptidase-4; FPG; fasting plasma glucose; GI; gastrointestinal; GLP-1; glucagon-like peptide-1; HbA1c; glycated hemoglo
Keywords: Intestine; Lipoprotein; Chylomicron; GLP-1; GLP-2; Resveratrol; Apo; apolipoprotein; CVD; cardiovascular diseases; DPP-4; dipeptidyl peptidase-4; FFA; free fatty acids; GIP; gastric inhibitory polypeptide; GLP-1; glucagon-like peptide-1; GLP-2; glucagon-l
Keywords: AGE; advanced glycation end product; aBMD; areal bone mineral density; BMD; bone mineral density; BMI; body mass index; DPP-4; dipeptidyl peptidase-4; DXA; dual-energy X-ray absorptiometry; eBMD; estimated bone mineral density; GLP-1; glucagon-like peptid
Keywords: ACE-I; angiotensin-converting enzyme inhibitor; ARB; angiotension receptor blocker; BMI; body mass index; Cr; creatinine; CVD; cardiovascular disease; DPP-4; dipeptidyl peptidase 4; GAD-65; glutamic acid decarboxylase; GLP-1; glucagon-like peptide 1; GFR;
Keywords: Type 2 diabetes; Cardiovascular; Glucose; GLP-1; DPP-4; SGLT-2
Keywords: AAV1; adeno-associated virus serotype 1; ACC; American College of Cardiology; ACCELERATE; A Study of Evacetrapib in High-Risk Vascular Disease; ACCORD; Action to Control Cardiovascular Risk in Diabetes; ADA; American Diabetes Association; AMP; adenosine m
Keywords: GLP-2; glucagon-like peptide-2; p-CTX; plasma-carboxy-terminal telopeptide of type 1 collagen; AUC; area under the curve; pmol; picomole; nmol; nanomole; mg; milligram; DPP-4; dipeptidylpeptidase-4; cm; centimeter; kg/m2; kilogram/square meter; EDTA; etyl
Keywords: AGEs; advanced glycation endproducts; BMD; bone mineral density; CAH; congenital adrenal hyperplasia; DM; diabetes mellitus; DPP-4; dipeptydil petptidase-4; DXA; dual-energy X-ray absorptiometry; FRAX; fracture risk assessment tool; FSH; follicle stimulat
Keywords: T2DM; type 2 diabetes mellitus; MI; myocardial infarction; CAD; coronary artery disease; I R injury; ischemia reperfusion injury; LV; left ventricle; DPP-4; dipeptidyl peptidase-4; GLP-1; glucagon-like peptide-1; PPARs; peroxisome proliferators-activated
Keywords: DPP-4; dipeptidyl peptidase-4; GLP-1; glucagon-like peptide-1; IRS-2; insulin receptor substrate-2; CREB; cAMP response element-binding protein; Gck; glucokinase; GIR; glucose infusion rate(s); EGP; endogenous glucose production; Rd; rate of glucose disap
Keywords: Plasminogen; DPP-4; Glucose tolerance
Malondialdehyde-modified LDL-related variables are associated with diabetic kidney disease in type 2 diabetes
Keywords: Malondialdehyde-modified low-density lipoprotein; Type 2 diabetes; Albuminuria; Estimated glomerular filtration rate; Dyslipidemia; AER; albumin excretion rate: BMI, body mass index; CKD; chronic kidney disease; CVD; cardiovascular disease; DPP-4; dipepti
Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes
Keywords: DPP-4; dipeptidyl peptidase-4; GIP; glucose-dependent insulinotropic polypeptide; GLP-1; glucagon-like peptide-1; GRP; gastrin-releasing peptide; NEP; neutral endopeptidase; OXM; oxyntomodulin; PACAP; pituitary adenylate cyclase-activating polypeptide; PY
GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice
Keywords: Glucagon-like peptide-1; Glucose metabolism; Vagus nerve; Liraglutide; Brain stem; Pancreatic β-cell proliferation; AP; Area postrema; ARC; Arcuate nucleus; AChR; Acetylcholine receptor; α-MSH; Alpha-melanocyte-stimulating hormone; BBB; Blood brain barr